Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.001
Neutral
RSI(14)
42.946
Neutral
STOCH(KDJ)(9,3,3)
61.090
Buy
ATR(14)
0.052
Low Volatility
CCI(14)
-3.319
Neutral
Williams %R
52.941
Neutral
TRIX(12,20)
-0.162
Sell
StochRSI(14)
72.760
Neutral
Search
XBiotech Inc
XBITAdd to Watchlist
2.280USD
+0.020+0.88%
Close 07-28 16:00（ET）Quotes delayed by 15 min
69.51MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.88%
5 Days
+1.33%
1 Month
-2.15%
6 Months
-15.87%
Year to Date
-4.60%
1 Year
-20.56%
Key Figures
2.260Open
2.310High
16.37KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.05%Turnover Ratio
2.260Prev. Close
2.256Low
30.75KTurnover
LossP/E Static
0.51P/B
0.00%Div Yield TTM
-24.97%ROA
3.62052wk High
0.28Volume Ratio
-38.53MNet Profit
30.49MShares
-1.3173EPS TTM
0.81Beta
-25.93%ROE
2.09052wk Low
2.41%Amplitude
94.67%Gross Margin
69.51MMarket Cap
-1.08Reward/Risk
2.78%Risk Rate
TradingKey Stock Score of XBiotech Inc
Currency: USD Updated: 2026-07-27Key Insights
XBiotech Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 200 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
XBiotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
XBiotech Inc Highlights
StrengthsRisks
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -1.72, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
XBiotech Inc News
More news coming soon, stay tuned...
Indicators
Moving Average
Indicators
Value
Direction
MA5
2.270
Buy
MA10
2.269
Buy
MA20
2.297
Sell
MA50
2.344
Sell
MA100
2.378
Sell
MA200
2.415
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
XBiotech Inc Info
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
Ticker SymbolXBIT
CompanyXBiotech Inc
CEOSimard (John)
Websitehttps://www.xbiotech.com/
Shareholders
Related Instruments
+1.98%
+0.31%
+1.71%
+2.50%
+0.83%
+2.37%
+4.42%
+2.57%
+2.92%
+2.37%
+1.72%
+2.35%
+3.47%
+3.33%
+4.61%
0.00%
+4.24%
+0.60%
+1.34%
-1.93%Popular Instruments
FAQs
What is the current price of XBiotech Inc (XBIT)?
The current price of XBiotech Inc (XBIT) is 2.27.
What is the symbol of XBiotech Inc?
The ticker symbol of XBiotech Inc is XBIT.
What is the 52-week high of XBiotech Inc?
The 52-week high of XBiotech Inc is 3.62.
What is the 52-week low of XBiotech Inc?
The 52-week low of XBiotech Inc is 2.09.
What is the market capitalization of XBiotech Inc?
The market capitalization of XBiotech Inc is 69.21M.
What is the Earnings Per Share (EPS TTM) of XBiotech Inc (XBIT)?
The Earnings Per Share (EPS TTM) of XBiotech Inc (XBIT) is -1.49.